Don’t Bogart That Labeling – Cesamet “Not Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of Valeant’s cannabinoid agonist for chemotherapy-induced emesis, which had been marketed by Lilly before 2004, remains on hold as FDA seeks more information on adverse events.
You may also be interested in...
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Valeant will also study the cannabinoid-receptor agonist in combination with other anti-emetics.
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Valeant will also study the cannabinoid-receptor agonist in combination with other anti-emetics.
Valeant Cesamet Slated To Hit Market In “Next Several Weeks”
Approval comes with indication restricting use to patients who don’t respond to conventional antiemetics due to concern over “disturbing psychotomimetic reactions.”